Acrotech Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ACROTECH, and what generic alternatives to ACROTECH drugs are available?
ACROTECH has six approved drugs.
There are twelve US patents protecting ACROTECH drugs.
There are one hundred and seventy-nine patent family members on ACROTECH drugs in thirty-four countries and six supplementary protection certificates in five countries.
Drugs and US Patents for Acrotech
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Acrotech Biopharma | BELEODAQ | belinostat | POWDER;INTRAVENOUS | 206256-001 | Jul 3, 2014 | RX | Yes | Yes | 8,835,501 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Acrotech Biopharma | EVOMELA | melphalan hydrochloride | POWDER;INTRAVENOUS | 207155-001 | Mar 10, 2016 | RX | Yes | Yes | 9,493,582 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Acrotech Biopharma | KHAPZORY | levoleucovorin | POWDER;INTRAVENOUS | 211226-001 | Oct 19, 2018 | RX | Yes | Yes | 11,541,012 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Acrotech Biopharma | FUSILEV | levoleucovorin calcium | POWDER;INTRAVENOUS | 020140-001 | Mar 7, 2008 | AP | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Acrotech Biopharma | BELEODAQ | belinostat | POWDER;INTRAVENOUS | 206256-001 | Jul 3, 2014 | RX | Yes | Yes | 6,888,027 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Acrotech Biopharma | EVOMELA | melphalan hydrochloride | POWDER;INTRAVENOUS | 207155-001 | Mar 10, 2016 | RX | Yes | Yes | 11,020,363 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Acrotech
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Acrotech Biopharma | FUSILEV | levoleucovorin calcium | SOLUTION;INTRAVENOUS | 020140-003 | Apr 29, 2011 | 6,500,829 | ⤷ Try a Trial |
Acrotech | MARQIBO KIT | vincristine sulfate | INJECTABLE, LIPOSOMAL;INTRAVENOUS | 202497-001 | Aug 9, 2012 | 7,247,316 | ⤷ Try a Trial |
Acrotech | MARQIBO KIT | vincristine sulfate | INJECTABLE, LIPOSOMAL;INTRAVENOUS | 202497-001 | Aug 9, 2012 | 5,814,335 | ⤷ Try a Trial |
Acrotech | MARQIBO KIT | vincristine sulfate | INJECTABLE, LIPOSOMAL;INTRAVENOUS | 202497-001 | Aug 9, 2012 | 5,543,152 | ⤷ Try a Trial |
Acrotech | MARQIBO KIT | vincristine sulfate | INJECTABLE, LIPOSOMAL;INTRAVENOUS | 202497-001 | Aug 9, 2012 | 6,723,338 | ⤷ Try a Trial |
Acrotech | MARQIBO KIT | vincristine sulfate | INJECTABLE, LIPOSOMAL;INTRAVENOUS | 202497-001 | Aug 9, 2012 | 7,887,836 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ACROTECH drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Injection | 50 mg/vial | ➤ Subscribe | 2017-09-08 |
➤ Subscribe | Injection | 50 mg/vial | ➤ Subscribe | 2013-12-19 |
➤ Subscribe | Injection | 500 mg/vial | ➤ Subscribe | 2018-07-03 |
➤ Subscribe | Injection | 10 mg/mL, 17.5 mL vial and 25 mL vial | ➤ Subscribe | 2011-10-26 |
➤ Subscribe | Injection | 20 mg/mL and 40 mg/2 mL | ➤ Subscribe | 2013-09-24 |
International Patents for Acrotech Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
South Africa | 201904909 | ⤷ Try a Trial |
South Korea | 20080016636 | ⤷ Try a Trial |
Slovenia | 1750716 | ⤷ Try a Trial |
South Korea | 101189693 | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 2010138920 | ⤷ Try a Trial |
Brazil | 112015008954 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Acrotech Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2701720 | 3/2023 | Austria | ⤷ Try a Trial | PRODUCT NAME: MELPHALANFLUFENAMID-HYDROCHLORID; REGISTRATION NO/DATE: EU/1/22/1669 (MITTEILUNG) 20220818 |
2701720 | CA 2022 00054 | Denmark | ⤷ Try a Trial | PRODUCT NAME: MELPHALAN FLUFENAMIDE HYDROCHLORIDE; REG. NO/DATE: EU/1/22/1669 20220818 |
2701720 | CR 2022 00054 | Denmark | ⤷ Try a Trial | PRODUCT NAME: MELPHALAN FLUFENAMIDE HYDROCHLORIDE; REG. NO/DATE: EU/1/22/1669 20220818 |
2701720 | 122023000007 | Germany | ⤷ Try a Trial | PRODUCT NAME: MELPHALANFLUFENAMID HYDROCHLORID; REGISTRATION NO/DATE: EU/1/22/1669 20220817 |
2701720 | 301206 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: MELPHALAN FLUFENAMIDE HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/22/1669 20220818 |
2701720 | 23C1000 | France | ⤷ Try a Trial | PRODUCT NAME: MELPHALAN FLUFENAMIDE ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, TELS QUE LE CHLORHYDRATE; REGISTRATION NO/DATE: EU/1/22/1669 20220818 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.